Kornimate/medical-research-clean huggingface dataset:
genetic, serological fecal and clinical markers in siblings of children with inflammatory bowel disease

Conditions: Inflammatory Bowel Disease

Summary: although the precise etiology of inflammatory bowel disease (ibd) is still unknown, over the last decade active research allowed to gain more precise insights in the pathophysiology of ibd indicating that the chronic inflammation of the intestinal mucosa is directed against the microbiota of the gut in particularly susceptible individuals. genetic studies and more recently genome-wide association studies (gwas) have allowed to identify over 70 susceptibility genes which confer an increased risk of developing ibd. in the last years the attention of researchers has shifted to the identification of the early immunological changes that occur already at a preclinical stage of the disease, trying also at identifying the disease before it shows itself. recently, the ability of a combination of serological markers in predicting the development of ibd has been demonstrated in adults. however, there are no studies evaluating a cohort of children at high risk for the disease, in whom the first immunological changes underlying the development of ibd could be studied, including a combination of genetic, serological, fecal and clinical markers. the purpose of this study is to evaluate in a population genetically well-characterized, as siblings and twins of patients affected with ibd, early genetic, serologic, fecal and clinical markers of disease, which may be present even years before developing the disease. the identification of these markers in predisposed individuals could help to implement strategies for prevention or early treatment to modify the natural history of ibd.

this is a multicenter, prospective, study evaluating the role of serological, genetic, fecal and clinical markers in predicting the development of ibd in a high risk population. the study will be divided in two phases. in the first phase the prevalence of genetic, serologic, fecal, clinical risk factors in 100 siblings of children affected with ibd compared to 100 healthy children with no family history for ibd will be evaluated. the estimated duration of the first phase of the study is 12 months. in a second phase, a long-term follow-up (5 years) will be performed in order to evaluate the accidental cases of ibd in this population.

Eligibility criteria:
inclusion criteria: * siblings of children affected with ibd * children without a family history of ibd exclusion criteria: * age \> 18 years * age \< 6 years * concomitant autoimmune disorders

Keywords: inflammatory bowel disease siblings
peer support for weight loss maintenance

Conditions: Obesity

Summary: the primary aim of this study is to test the efficacy of patient-provided treatment for weight-loss maintenance.


Eligibility criteria:
inclusion criteria: * age between 18-75 * body mass index between 25-50 * english speaking exclusion criteria: * report being unable to walk 2 blocks without stopping * are currently participating in weight loss treatment, have a history of bariatric surgery, or lost ≥5% in the past 6-months * are pregnant or plan to become pregnant within 1 year * report a heart condition, chest pain during periods of rest or activity, or loss of consciousness on the physical activity readiness questionnaire * report a medical condition that could jeopardize their safety in a weight control program with diet and exercise guidelines * report conditions that, in the judgment of the pi, would render them unlikely to follow the protocol (e.g., relocation, dementia, unable to read and write in english) * have no internet access.

Keywords: weight loss weight maintenance weight control peer support patient-provided care
influence of lachrymal substitute gels on tear film thickness in patients with moderate to severe dry eye syndrome

Conditions: Dry Eye Syndromes

Summary: dry eye syndrome is a highly prevalent ocular disease with an increasing incidence in the elderly population. topically administered lubricants are the basis for treatment of this disease. however, exact information about the tear film thickness and the corneal residence time of topical lubricants is still sparse, therefore no ideal treatment regimen has been found. recently a new method for assessment of tear film thickness based on ultra high resolution optical coherence tomography (oct) has become available. the aim of the present study is to assess tear film thickness and corneal residence time of three different formulations of topical lubricants, in particular thealoz duo® eye drops, hylo® gel eye drops and systane® gel eye drops in patients with moderate to severe dry eye disease. in addition, standard tests for dry eye syndrome, such as the ocular surface disease index (osdi©), schirmer i test and determination of tear break up time (but) will be performed.


Eligibility criteria:
inclusion criteria: 1. men and women aged over 18 years 2. signed and dated written informed consent 3. history of dry eye syndrome for at least 3 months 4. tear break up time (but) ≤ 10 seconds or schirmer i test ≤ 5 mm and ≥ 2mm 5. osdi ≥ 22 6. normal ophthalmic findings except dry eye syndrome, ametropia \< 6 dpt. 7. no administration of topical lubricants 12-24 hours before the screening examination exclusion criteria: 1. presence of an ocular pathology judged by the investigator as incompatible with the study. 2. any other clinical relevant ocular abnormality except des. 3. history of allergy, known hypersensitivity to one of the components: the study medications or fluorescein. 4. history of known clinically relevant allergy. 5. medical or surgical history judged by the investigator to be incompatible with the study participation (hepatic or renal insufficiency; all chronic severe organic disease: metabolic, endocrine, neoplastic, haematological disease; severe psychiatric illness, etc.). 6. history of a recent acute illness with a recovery period within the 2 weeks before the inclusion visit (day 0). 7. pregnancy, lactation. 8. pre-menopausal woman who is not using a reliable birth control method (oral contraceptives or coil) or is not surgically sterilised. 9. participation in any high-speed or water-sports during the study without ocular protection (goggles or glasses). 10. subject unable to understand the study instructions or unlikely to comply with the study schedule and treatment. 11. participation in another clinical study in the 4 weeks before the start of the present study or at the same time as the present study. 12. subject is a ward of court.
topical cryotherapy in reducing pain in patients with chemotherapy induced peripheral neuropathy or paclitaxel induced acute pain syndrome

Conditions: Breast Carcinoma

Summary: this randomized pilot clinical trial studies topical cryotherapy (cooling hands and feet with ice bags) in reducing pain in patients with chemotherapy induced peripheral neuropathy or paclitaxel induced acute pain syndrome. peripheral neuropathy is a nerve problem that causes pain, numbness, tingling, swelling, or muscle weakness in different parts of the body. paclitaxel produces a disabling syndrome of acute aches and pains. topical cryotherapy is being studied to see if it can help relieve pain from peripheral neuropathy or acute pain syndrome caused by chemotherapy.

primary objectives: i. to estimate whether topical cryotherapy can alleviate paclitaxel-induced peripheral neuropathy. ii. to estimate whether topical cryotherapy can alleviate paclitaxel-induced acute pain syndrome (p-aps). iii. to examine the possible relative toxicities related to topical cryotherapy in this study situation. outline: patients are randomized to 1 of 2 arms. arm i: patients apply bags filled with crushed ice to hands and feet for 15 minutes before, for 60 minutes during administration, and for 15 minutes after finishing administration of paclitaxel. arm ii: patients receive paclitaxel intravenously (iv) over 60 minutes on weeks 1-12. in both arms, courses repeat once a week for 12 weeks in the absence of disease progression or unacceptable toxicity. after completion of study treatment, patients are followed up every 30 days for 6 months.

Eligibility criteria:
inclusion criteria: * ability to complete questionnaires by themselves or with assistance * planned paclitaxel at a dose of 80 mg/m\^2 intravenously (i.v.) given, in the adjuvant breast cancer (postoperative or neo-adjuvant) setting, every week for a planned course of 12 weeks without any other concurrent cytotoxic chemotherapy (note: trastuzumab and/or other antibody and/or small molecule treatment is allowed, except for poly adenosine diphosphate ribose polymerase \[parp\] inhibitors), at the entering academic and community cancer research united (accru) institution * life expectancy \> 6 months * eastern cooperative oncology group (ecog) performance status 0 or 1 * patient has score of 0 or 1 on the neurotoxicity evaluation, as determined by the healthcare provider exclusion criteria: * previous diagnosis of diabetic neuropathy or peripheral neuropathy from any cause * diagnosis of fibromyalgia * any prior exposure to neurotoxic chemotherapy * history of raynaud?s disease, cryoglobulinemia
cardiopulmonary rehabilitation for post-acute covid-19 symptoms

Conditions: Cardiopulmonary

Summary: the purpose of this retrospective study was to compare the effect of a hospital and home-based cardiopulmonary rehabilitation (cpr) program on exercise endurance and quality of life in post-acute covid-19 patients. 88 post-acute covid-19 patients were divided two groups according to receiving hospital (n=45) or home-based cpr (n=43)in our rehabilitation clinic between january and july 2021. both protocols consisted of aerobic, breathing and flexibility exercises. hospital-based cpr: three or four days per week for a total of 20 sessions. home-based cpr: three or four days/a week over a period of six weeks. the results of six meters walk test (6mwt) for exercise endurance as a main outcome measure, and borg-dyspnea/fatigue, the visual analog scale (vas) for pain and the short form-36 (sf-36) as secondary outcome measures before and after treatment were recorded.


Eligibility criteria:
inclusion criteria: * being 18 years or older * having covid-19 treatment (home quarantine/hospital/intensive care unit) according to a positive polymerase chain reaction (pcr) test in a nasopharyngeal + oropharyngeal swab or chest computed tomography (ct) * participating in a home-based exercise program (for 6 weeks) or hospital-based cpr (for 12-20 sessions) due to post-acute covid-19 symptoms (fatigue, myalgia, dyspnea). exclusion criteria: * patients who had both a negative pcr test and chest ct * patients who had not completed the six minute walk test (6mwt), borg scales, short form-36 and visual analog scale-pain. * acute covid-19 patients (patients whose symptoms had started less than one month previous)
improving clinical pet/ct image quality in retrospectively reconstructed breath-hold images

Conditions: Lung Cancer

Summary: the patient has been referred for an fdg pet/ct scan. fdg is a form of sugar that contains a small amount of radioactivity; it is used to see the size and possible spread of cancer in the body. pictures of the body are taken on a machine called a pet/ct scanner. the purpose of this current study is to see if we, the investigators, can take clearer pictures of the tumor than we could with our routine scan method. this would allow us to better see how fdg is picked up by the tumor. pet/ct is presently one of the best tools for detecting cancer and determining its spread in the body. however, due to breathing motion, pet and ct images may become blurred and the location of the tumor on ct and pet images may not match. we have developed a new method that enables us to reduce image blurring and to measure the tumor more accurately on pet images. in this study we want to compare two kinds of images: those from the standard pet/ct scan, and the pet/ct scan pictures taken with our new method. if successful, we may use this new method for clinical routine in the future.


Eligibility criteria:
inclusion criteria: * participant is capable of providing written consent. * 18 years of age or older. * patient with a known or suspected fdg-avid malignancy in the torso exclusion criteria: * none

Keywords: lung pet/ct scan 10-054
nurse-led consultations in heart failure within the 'fil-eas' evaluation and support care pathway for heart failure patients

Conditions: Chronic Heart Failure

Summary: the management of chronic heart failure, following current guidelines, requires the implementation and adjustment of therapies to limit mortality and morbidity associated with disease progression. however, this period of treatment titration remains challenging due to the need for multiple, closely spaced consultations. the difficulty in maintaining this consultation frequency, coupled with the current decline in medical demographics, largely explains the lack of treatment titration or even initiation and the existing therapeutic inertia. concurrently, medical telemonitoring is emerging as an essential tool in heart failure management, offering significant benefits for both patients and healthcare professionals. in this context, new forms of nursing practices have emerged, such as advanced practice nursing, aimed at improving the care of patients with chronic diseases. however, only limited data are currently available regarding the functioning and impact of these consultations in france. the "evaluation and support pathway for heart failure patients (fil-eas ic)" has systematically integrated this new model of consultations provided by heart failure nurse specialists. given their significant and growing role within the pathway, it appears necessary to thoroughly evaluate these consultations to propose improvements and maximize their effectiveness.


Eligibility criteria:
inclusion criteria: * aged 18 years old or over * patient seen in nurse-led consultations for heart failure between january 1, 2023 and december 31, 2023 exclusion criteria: * patient opposition to participate in the study

Keywords: chronic heart failure nurse heart failure nurse specialists advanced practice nursing treatment titration care pathway
carbapenem antibiotic therapy for vim carbapenemase-producing enterobacteriaceae infections

Conditions: Carbapenemase-Producing Enterobacteriaceae

Summary: carbapenemase-producing enterobacteriaceae (cpe) infections are emerging infections that pose a therapeutic challenge. these infections mainly occur in patients with prolonged hospitalization and repeated exposure to antibiotics. certain strains, notably vim-producing strains, may remain sensitive to carbapenems. cpe vim strains are rare in france, but represent the main cpe strains in many countries. they are historically the main type of carbapenemases isolated at the strasbourg university hospital.

the circulation of multi-antibiotic-resistant bacterial strains is significant at the strasbourg university hospital and the investigators wish to report their local experience in the use of carbapenems in infections with enterobacteria producing carbapenemase type vim.

Eligibility criteria:
inclusion criteria: * adult patient (≥18) * treated at the hus for a vim-producing enterobacteria infection between 01/01/2011 and 11/30/2022 * subjects who have not expressed their opposition to the reuse of their data for scientific research purposes. exclusion criteria: * patient having expressed his opposition to the retrospective reuse of his data for scientific research purposes.

Keywords: carbapenemase enterobacteriaceae vim-producing strains
controlling post-extraction complications of impacted mandibular third molar

Conditions: Preventing Postextraction Complication

Summary: impacted mandibular 3rd molar will be extracted in all patients, then patients will be divided, according to material placed in extraction socket into 3 groups: control, hyaluronic acid and honey. then post extraction complications will be evaluated

impacted mandibular third molar will be extracted under local anesthesia through standard surgical flap elevation, after extraction and wound irrigation a material facilitate healing will be placed. according to material will be placed patients will be divide into 3 group: control ( no material, second group hyaluronic acid, third group ( honey).. then wound will be closed. postoperative pain ( through visual analog scale) , edema, total dose of analgesic, mandibular movement (interincisal distance in mm) will be evaluated preoperative, 1,2,3,7, and 10 day after extraction

Eligibility criteria:
inclusion criteria: * healthy patients * patient has impacted 3rd molar exclusion criteria: * medically compromised patients heavy smoking patients
pilot simplification study to lopinavir/ritonavir 800/200 mg monotherapy regimen once daily

Conditions: HIV

Summary: lopinavir/ritonavir monotherapy is currently a well known and widely used strategy, while lopinavir/ritonavir 800/200 mg once a day in a triple-therapy was approved a few years ago. the purpose of this study is to evaluate efficacy and safety of lopinavir/ritonavir 800/200 mg monotherapy once a day.


Eligibility criteria:
inclusion criteria: * patients older than 18, hiv positive * patients receiving a monotherapy regimen (lopinavir/ritonavir twice daily)during the last 6 months * undetectable viral load (\<40 copies/ml) during the last 6 months * patients that accept participation in the study and sign the informed consent form * childbearing females with negative pregnancy tests and using appropriate contraceptive measures exclusion criteria: * opportunistic disease, cancer or any other active disease with specific treatment * active addiction to illegal drugs or active use of psychotropic drugs * mental retardation diagnosis, or mental dementia or severe psychiatric disorder (excluding major depression disorder solved \> 3 months) * females who are breastfeeding or pregnant

Keywords: hiv aids monotherapy pilot lopinavir/ritonavir
xp-endo finisher on postoperative pain in retreatment cases using mtwo r files

Conditions: Dental Pain; Endodontically Treated Teeth

Summary: introduction: postoperative pain is one of the most critical issues in our daily practice. , postoperative pain control is essential for patient satisfaction and comfort. when primary root canal treatment fails, root canal retreatment aims to heal apical periodontitis. aim of study: to compare between postoperative pain (pos) after endodontic retreatment using ni-ti rotary files mtwo r alone and in conjunction with xp endo finisher . materials and methods: this research is a randomized clinical trial conducted in a parallel design on 50 patients needing retreatment. they will be divided into two groups, group 1 retreatment with mtwo r, group 2 retreatment with mtwo r followed by xp - endo finisher. postoperative pain levels will be evaluated at 24 hours, 48 hours, 72 hours, and 7 days following the removal of the obturation mat erial. the assessment of pain will be done through clinical examination, the defense and veterans pain rating scale (dvprs) and by the intake of pain killer


Eligibility criteria:
inclusion criteria: * teeth with mature apices. * patients with no systemic diseases. * no analgesic, anti-inflammatory, or antibiotic intake during 7 days before treatment. * teeth showing failure of initial root canal treatment and radiograph evidence of periapical bone destruction exclusion criteria: * multi rooted teeth. * teeth with open apices. * teeth with cracks, calcification, root caries, fractures, external or internal resorption. * allergies to local anesthetic agents. * presence of severe pain and/or acute apical abscesses
behavioral economics applications to geriatrics leveraging ehrs r33 trial

Conditions: Prostate Specific Antigen Screening; Asymptomatic Bacteriuria; Type 2 Diabetes

Summary: investigators will evaluate clinical decision support nudges informed by behavioral science and directed at primary care clinicians. these will be used to reduce commonly misused, and potentially harmful, diagnostic and therapeutic actions that occur in the care of older adults (e.g. overtreatment of type 2 diabetes, misuse of psa screening, misuse of urine testing in women with nonspecific symptoms or no symptoms.

diagnostic and therapeutic strategies misapplied to older adults can lead to increased morbidity and mortality. despite recommendations from the american geriatrics society for the choosing wisely initiative, there are clear examples where clinicians do not often follow best practices leading to patient harm. these include: (1) testing and treatment for asymptomatic bacteriuria (asb) in older women, (2) prostate specific antigen (psa) screening in older men, and (3) aggressive treatment with insulin or oral hypoglycemics for type 2 diabetes. clinical decision support nudges, informed by behavioral economics and social psychology and delivered via electronic health records (ehrs), are promising strategies to reduce the misuse of services. behavioral economics-informed interventions influence conscious and unconscious drivers of decision making, are low cost, and can be incorporated into existing systems. this randomized controlled trial will evaluate the effects of three clinical decision support nudges on three clinical quality measures, indicators of patient safety, and clinician attitudes.

Eligibility criteria:
inclusion criteria: * northwestern medicine primary care clinician who sees patients under department code of a randomized clinic exclusion criteria: * resident physicians will be excluded * clinicians who participated in pilot study of these interventions * clinician study investigators

Keywords: geriatrics quality of care
mindfulness-based sex therapy on patients with takotsubo cardiomyopathy

Conditions: Takotsubo Cardiomyopathy; Sexual Dysfunction

Summary: takotsubo cardiomyopathy (tc) is a type of non-ischemic cardiomyopathy in which there is a sudden temporary weakening of the myocardium. . in a recent study, women report more sexual dysfunction than men after 1 year after tc. despite that a number of studies have assessed female sexual dysfunction (fsd) for tc , there is no information regarding prevalence and associated factors on fsd in women with tc. however, in a recent study on iranian female patients with tc, more than 77% of these patients suffered from fsd. this study is aimed to assess the effectiveness of a mindfulness-based sex therapy on patients with tc.


Eligibility criteria:
inclusion criteria: * aged 18 years old at least * confirmed diagnosis of tc by a cardiologist according mayo clinic diagnostic criteria; an acute left ventricular apical ballooning of unknown cause * willingness to partaking for the duration of the trial * a basic fluency in persian * living with a partner/spouse exclusion criteria: * cognitive disability * having acute myocardial infarction * cerebrovascular disease * pheochromocytoma and viral or idiopathic myocarditis * , participating in another rct